Men prescribed testosterone therapy despite no symptoms of hypogonadism have higher risk for major adverse cardiovascular events and all-cause mortality than men with hypogonadism using testosterone therapy, researchers reported. In an analysis of data from the TriNetX global collaborative network published in eBioMedicine, researchers found risks for several CV events with testosterone therapy